Structure Therapeutics Inc. (NASDAQ:GPCR) Sees Large Decline in Short Interest

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) was the target of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 7,850,000 shares, a decrease of 20.4% from the January 15th total of 9,860,000 shares. Based on an average daily trading volume, of 885,400 shares, the short-interest ratio is presently 8.9 days. Approximately 14.5% of the company's shares are sold short.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on GPCR shares. Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 target price on the stock. JMP Securities restated a "market outperform" rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $81.29.

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. ANTIPODES PARTNERS Ltd raised its stake in Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after buying an additional 553 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after acquiring an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Structure Therapeutics in the 4th quarter worth about $34,000. FNY Investment Advisers LLC bought a new position in Structure Therapeutics in the 4th quarter worth about $40,000. Finally, Assetmark Inc. grew its position in Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after purchasing an additional 719 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Trading Up 3.8 %

GPCR traded up $0.86 during midday trading on Wednesday, reaching $23.58. The company's stock had a trading volume of 359,262 shares, compared to its average volume of 786,134. Structure Therapeutics has a 1 year low of $22.33 and a 1 year high of $62.74. The stock's 50-day moving average is $27.90 and its 200-day moving average is $34.26. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -31.73 and a beta of -2.75.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.